| Market Cap | $2.96B+7.5% |
| Revenue (ttm) | $21.38M |
| Net Income | -$314.42M |
| EPS | -$1.72 |
| Shares Out | 160.29M |
| PE Ratio | n/a |
| Forward PE | -8.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,632,241 |
| Open | $17.95 |
| Previous Close | $18.20 |
| Day's Range | $17.92 - $18.85 |
| 52-Week Range | $15.34 - $27.30 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | $35.82(+94.17%) |
| Earnings Date | Nov 3, 2026 |
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating DNLI in the last 3 months, one vote each. Issuer-paid research is not counted.
$DNLI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DNLI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DNLI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DNLI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DNLI Revenue by Segment
| Gain on sale of priority review voucher, net | $194.00M | 98.54% |
| Segment interest and other income, net | $2.88M | 1.46% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DNLI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DNLI from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from DNLI’s recent data — informational, not investment advice
What’s Behind the Score
News check: Wells Fargo initiated coverage with Overweight rating and $35 price target; pipeline milestones nearing with expanded Hunter Disease patient targeting represent concrete positive catalysts.
Recent Insider Activity
Insider Score Trend Over Time
-48.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| MNTL | Tema Neuroscience And Mental Health ETF | 1.98% |
| SBIO | ALPS Medical Breakthroughs ETF | 1.98% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 1.72% |
| BBP | Virtus Biotech ETF | 1.17% |
| TDNA | T. Rowe Price Biotech ETF | 1.08% |
| BGUS | Baillie Gifford U.S. Equity Growth ETF | 0.61% |
| XBI | State Street SPDR S&P Biotech ETF | 0.58% |
| TSEE | T. Rowe Price Small Cap ETF | 0.42% |
| NIXT | Research Affiliates Deletions ETF | 0.42% |
| TCAF | T. Rowe Capital Appreciation Equity ETF | 0.32% |
| LNGR | Global X Aging Population ETF | 0.30% |
| TMID | T. Rowe Price Mid Cap Equity Research ETF | 0.26% |
Weight is the stock’s share of each fund’s holdings.
